THERASAM
Localized radiotherapy, using Holmium with purpose and precision
Ghost: An innovative Holmium-Based Platform
Ghost by TheraSAM is a holmium-based radiotherapeutic of neutron irradiated microspheres that delivers precise, localized beta and gamma radiation to solid tumors.
LOW-COST HOLMIUM
Rare earth element.
Short activation time (1h).
Quick radioactive decay (26h).
Magnetic properties.
GLASS
Resistance to melting.
Structural and thermal stability.
Low radiation activation.
Higher radioactive loading vs PLLA — improving logistics window and clinical effectiveness.
Ghost microspheres are developed by gluing holmium on the surface of glass microspheres
A value proposition meeting the needs of patients HCPs, and HC
system
TheraSAM offers significant value to patients, doctors, and hospitals & clinics, while enhancing patient outcomes for both candidates and non-candidates for radio-chemo-immunotherapy.
1
For Patients
Receive a highly targeted, minimally invasive treatment that increases survival rate,
reduces recurrence and side effects, enabling faster recovery and fewer complications compared to systemic therapies.
2
For Healthcare Professionals
Benefit from a safe, efficient, and precise loco-regional radiotherapy system that integrates easily with existing clinical workflows and allows for fully personalized cancer treatment, with no need for side-effects management.
3
For Hospital & Clinics
Achieve lower hospitalization and radiotherapy-related costs, improve infrastructure compatibility, and reduce overall treatment expenses without requiring major investments, reshaping the overall investment model toward a patient-based approach.
TheraSAM leading the way in precision loco-regional radiotherapy
Empowering oncology through precision loco-regional radiotherapeutics, TheraSAM develops innovative, holmium-based solutions to deliver highly localized and effective cancer treatments, minimizing side effects and maximizing clinical impact.
Why We Joined Forces
We bring together leading experts in nuclear physics, radiopharmacy, and surgical oncology. Driven by a shared belief in the untapped potential of holmium, we united to pioneer a new class of precision radiotherapeutics that bridge the gap between effectiveness and accessibility, from hospitals to outpatient settings.
Focus Area & Future Outlook
Our current focus is on oncology applications, with a primary target on medical-grade devices for loco-regional treatment. Given holmium’s unique characteristics and our capabilities, future expansion into other therapeutic areas or industries remains a strategic opportunity to leverage.
TEAM
Strong Scientific Team with 100+ years of experience in Oncology and Nuclear Science
Stephane Chauvie
Co-Founder
Medical Physicist with 30+ years of experience in oncology imaging, radioprotection, and clinical trial coordination.
Achille Cester
Co-Founder
Experienced engineer with 30+ years of expertise in radiation protection, industrial safety and risk management, and pressure equipment.
Maurizio Grosso
Co-Founder
Interventional Radiologist with 40+ years of clinical and academic experience, also leading specialized departments.
Daniela Santarelli
Acting CEO
Pharma Industry Leader with 25+ experience in Commercial,&
Access Strategy and Launch Excellence.
ADVISORY BOARD
Felice Borghi
Director of Oncologic Surgery at the Candiolo Cancer Institute.
Marcus Scaramanga
Co-Founder of Minnex & Nest Hotels, with a degree in Mechanical Engineering from the University of Bristol.
Lucrezia Cester
Ph.D. in Biomedical Imaging from the University of Glasgow, Founder of LightHearted AI, Forbes 30 Under 30.
Massimo Oddone
Radiochemist and Associate Professor of General Chemistry at the University of Pavia.
TheraSAM’s Unique Edge
- HOLMIUM-BASED MULTI-APPLICABILITY PLATFORM
- OPERATIONAL EXCELLENCE & MODEL READINESS
- WORLD-CLASS, CROSS-FUNCTIONAL TEAM
- SUSTAINABILITY AS A STRATEGIC LEVER
- MARKET WITH HIGH POTENTIAL